Survey data from a national poll indicate rising cannabis use in older adults, as access to cannabis increases across the country.
Cannabis use among older adults in the US increased since the COVID-19 pandemic in 2020, according to a study published in the journal Cannabis and Cannabinoid Research in November 2023 (1). Noting that there has been a lack of research in this area since 2019, the study, titled “Prevalence and Frequency of Cannabis Use Among Adults Ages 50–80 in the United States,” examined survey data from the National Poll on Healthy Aging (1). In the survey, 2,000 Americans answered questions about cannabis use over the course of the year (1). The study did not separate cannabis by medical or recreational uses (3).
“Among 2023 participants aged 50–80 (52.7% female), 12.1% reported cannabis use in the past year,” stated the Results in the Abstract (1). “Among those who reported cannabis use, 34.2% reported using cannabis products 4 or more days per week.”
The study also found that the respondents who used alcohol, or who were unemployed and unmarried were more likely to report cannabis use, while those who identified as Hispanic or “other” ethnicity were less likely to do so compared to those who identified as white (1).
“As the stress of the pandemic and the increased legalization of cannabis by states converged, our findings suggest cannabis use increased among older adults nationally,” stated Anne Fernandez, PhD, with the Addiction Center, Department of Psychiatry at the University of Michigan (3). “Older adults represent a vulnerable age group for cannabis use due to interactions with medications, risky driving, cannabis-related mental health impacts and increased possibility of falls and memory issues.”
As part of the conclusion of the study, the authors suggested more focus by medical professionals and policymakers on the health effects and risks for this population that uses cannabis (1).
References
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.